Understand the source comparison
Quickcomparison
Dose Range Substance P Antagonists 80 mg–125 mg mg KPV (Alpha-MSH Fragment) 200 mcg–1500 mcg mcg Frequency Once daily Administration Oral capsule Oral Cycle Length Ongoing/indefinite Onset Speed Moderate (1-2 weeks) Evidence Level Moderate human trials (Phase
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Dose Range
- Substance P Antagonists
- 80 mg–125 mg mg
- KPV (Alpha-MSH Fragment)
- 200 mcg–1500 mcg mcg
- Frequency
- Once daily
- Administration
- Oral capsule
- Oral
- Cycle Length
- Ongoing/indefinite
- Onset Speed
- Moderate (1-2 weeks)
- Evidence Level
- Moderate human trials (Phase 1-2)
- Strong human trials (Phase 3 or FDA approved)
- Efficacy